Table 3 Relationships between lymphoscintigraphic findings and therapy response
Qualitative lymphoscintigraphic indicators | Dichotomous early response (at 3Â months) | Dichotomous late response (at 1Â year) | |||||
|---|---|---|---|---|---|---|---|
Volume increase†| Volume decrease§ | p-value | Volume increase | Volume decrease | p-value | ||
Inguinal LN uptake | Absent | 4 (57.1%) | 3 (42.9%) | N-S | 4 (57.1%) | 3 (42.9%) | N-S |
| Â | Present | 5 (50.0%) | 5 (50.0%) | Â | 5 (50.0%) | 5 (50.0%) | Â |
Main lymphatic vessel | Absent | 5 (38.5%) | 8 (61.5%) | N-S | 6 (46.2%) | 7 (53.8%) | N-S |
| Â | Present | 4 (100.0%) | 0 (0.0%) | Â | 3 (75.0%) | 1 (25.0%) | Â |
Collateral vessel | Absent | 8 (53.3%) | 7 (46.7%) | N-S | 7 (46.7%) | 8 (53.3%) | N-S |
| Â | Present | 1 (50.0%) | 1 (50.0%) | Â | 2 (100.0%) | 0 (0.0%) | Â |
Dermal backflow (Pattern 1) | Absent | 4 (80.0%) | 1 (20.0%) | N-S | 4 (80.0%) | 1 (20.0%) | N-S |
| Â | Present | 5 (41.7%) | 7 (58.3%) | Â | 5 (41.7%) | 7 (58.3%) | Â |
Dermal backflow (Pattern 2) | Absent OR distal only | 7 (58.3%) | 5 (41.7%) | N-S | 7 (58.3%) | 5 (41.7%) | N-S |
| Â | Proximal only OR whole lower limb | 2 (40.0%) | 3 (60.0%) | Â | 2 (40.0%) | 3 (60.0%) | Â |
Dermal backflow (Pattern 3) | Absent OR proximal only | 6 (85.7%) | 1 (14.3%) | 0.050 | 6 (85.7%) | 1 (14.3%) | 0.050 |
| Â | Distal only OR whole lower limb | 3 (30.0%) | 7 (70.0%) | Â | 3 (30.0%) | 7 (70.0%) | Â |
Dermal backflow (Pattern 4) | Absent OR distal only OR proximal only | 9 (64.3%) | 5 (35.7%) | N-S | 9 (64.3%) | 5 (35.7%) | N-S |
| Â | Whole lower limb | 0 (0.0%) | 3 (100.0%) | Â | 0 (0.0%) | 3 (100.0%) | Â |
Quantitative lymphoscintigraphic indicators | Early response (at 3Â months) | Late response (at 1Â year) | |||||
|---|---|---|---|---|---|---|---|
N | Mean rank | p-value | N | Mean rank | p-value | ||
1 h LN uptake ratio | Volume increase†| 9 | 8.22 | N-S | 9 | 7.78 | N-S |
|  | Volume decrease§ | 8 | 9.88 |  | 8 | 10.38 |  |
1Â h Extremity uptake ratio | Volume increase | 9 | 7.56 | N-S | 9 | 7.44 | N-S |
| Â | Volume decrease | 8 | 10.63 | Â | 8 | 10.75 | Â |
1Â h Injection site clearance ratio | Volume increase | 9 | 9.56 | N-S | 9 | 9.78 | N-S |
| Â | Volume decrease | 8 | 8.38 | Â | 8 | 8.13 | Â |
2Â h LN uptake ratio | Volume increase | 9 | 8.11 | N-S | 9 | 7.67 | N-S |
| Â | Volume decrease | 8 | 10.00 | Â | 8 | 10.50 | Â |
2Â h Extremity uptake ratio | Volume increase | 9 | 7.33 | N-S | 9 | 6.44 | 0.027* |
| Â | Volume decrease | 8 | 10.88 | Â | 8 | 11.88 | Â |
2Â h Injection site clearance ratio | Volume increase | 9 | 8.22 | N-S | 9 | 8.00 | N-S |
| Â | Volume decrease | 8 | 9.88 | Â | 8 | 10.13 | Â |